statistiche ricercatore

Continente	#
NA - Nord America	488
AS - Asia	471
EU - Europa	252
SA - Sud America	71
Continente sconosciuto - Info sul continente non disponibili	19
AF - Africa	18
Totale	1.319

Nazione	#
US - Stati Uniti d'America	473
SG - Singapore	209
CN - Cina	102
IT - Italia	62
BR - Brasile	58
VN - Vietnam	37
FR - Francia	34
DE - Germania	33
IN - India	31
GB - Regno Unito	24
FI - Finlandia	20
IE - Irlanda	18
JP - Giappone	15
ID - Indonesia	13
KR - Corea	13
BD - Bangladesh	12
HK - Hong Kong	12
NL - Olanda	10
SE - Svezia	10
AR - Argentina	9
IQ - Iraq	8
RU - Federazione Russa	8
AT - Austria	7
CA - Canada	7
ES - Italia	7
ZA - Sudafrica	6
MA - Marocco	4
PL - Polonia	4
SA - Arabia Saudita	4
BE - Belgio	3
MX - Messico	3
AW - Aruba	2
CH - Svizzera	2
CZ - Repubblica Ceca	2
DZ - Algeria	2
HU - Ungheria	2
IL - Israele	2
LT - Lituania	2
OM - Oman	2
PK - Pakistan	2
UZ - Uzbekistan	2
VE - Venezuela	2
AO - Angola	1
BG - Bulgaria	1
BS - Bahamas	1
CI - Costa d'Avorio	1
EC - Ecuador	1
ET - Etiopia	1
GA - Gabon	1
GE - Georgia	1
HN - Honduras	1
IR - Iran	1
JO - Giordania	1
KE - Kenya	1
KZ - Kazakistan	1
LK - Sri Lanka	1
MY - Malesia	1
PY - Paraguay	1
RO - Romania	1
SI - Slovenia	1
SN - Senegal	1
TR - Turchia	1
TT - Trinidad e Tobago	1
UA - Ucraina	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.301

Nome	#
Advanced and recurrent endometrial cancer: State of the art and future perspectives	145
Recent progress in the use of pharmacotherapy for endometrial cancer	123
PARP Inhibitors Resistance: Mechanisms and Perspectives	123
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?	113
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study	110
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors	102
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives	95
Pembrolizumab for advanced cervical cancer: safety and efficacy	94
Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: A retrospective single-center experience	92
Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go beyond	87
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors	81
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors	79
Management of stage III and IVa uterine cancer	75
Totale	1.319

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	25	0	0	0	5	0	0	1	7	2	1	2	7
2022/2023	84	6	9	2	9	2	8	4	3	6	9	19	7
2023/2024	157	4	25	17	16	4	21	19	3	5	5	18	20
2024/2025	319	8	4	31	6	20	20	14	6	30	54	78	48
2025/2026	657	82	22	40	79	114	46	117	37	43	40	14	23
2026/2027	75	58	17	0	0	0	0	0	0	0	0	0	0
Totale													1.319

IRIS UniCatt